

CARACO PHARMACEUTICAL LABORATORIES LTD  
Form 8-K  
October 08, 2010

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

October 8, 2010 (Date of report)

CARACO PHARMACEUTICAL LABORATORIES, LTD.  
(Exact name of registrant as specified in its charter)

Michigan  
(State or other jurisdiction of  
incorporation)

1-31773  
(Commission file number)

38-2505723  
(I.R.S. employer identification no.)

1150 Elijah McCoy Drive, Detroit, Michigan 48202  
(Address of principal executive offices)

(313) 871-8400  
(Registrant's telephone number, including area code)

Not Applicable  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 140.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-



Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) and (c) On October 8, 2010, the Board appointed Gurpartap Singh Sachdeva to the position of Chief Executive Officer effective November 1, 2010, following the resignation of Jitendra N. Doshi as interim Chief Executive Officer and as a Director, effective November 1, 2010. The disclosures in the attached press release with respect to the appointment and business background of Mr. Singh and the resignation of Mr. Doshi are incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

The disclosure in the attached press release with respect to the status of the Company's remediation efforts is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

d. Exhibits.

| Exhibit No. | Description   |
|-------------|---|
| 99.1        | Press Release of Caraco Pharmaceutical Laboratories, Ltd., dated October 8, 2010. |

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CARACO PHARMACEUTICAL LABORATORIES, LTD.

Date: October 8, 2010

By: /s/ Jitendra N. Doshi  
Jitendra N. Doshi  
Chief Executive Officer

Exhibit Index

99.1 Press Release of Caraco Pharmaceutical Laboratories, Ltd., dated October 8, 2010.

2

---